- RECCE® 327 (R327) demonstrated >99% log reduction (>2.5 log reduction) in Mycobacterium abscessus lung infections using a nebulizer delivery method
- R327 is being evaluated for potential use to treat ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP)
“These results represent a significant milestone in the development of nebulized treatments for lung infections,” said
Sohinee Sarkar, Ph.D., lead researcher at Recce’s AIR unit, added, “The results are very promising and pave the way for future clinical applications. This could be particularly transformative for patients suffering from VAP and HAP, conditions that significantly increase morbidity and mortality rates in intensive care units.”
The pilot study demonstrated a significant reduction in Mycobacterium abscessus (M. abscessus) colonization in both lungs of mice treated with nebulized R327. Notably, the mice maintained a stable body weight throughout the study period, indicating the treatment’s safety and tolerability. This pilot study represents an important step toward exploring new methods of administration across a broad range of therapeutic indications.
The data builds on past preclinical studies where R327 demonstrated a dose-dependent killing of intracellular M. abscessus with no toxicity observed against treated human macrophages or in intranasally infected mice. Furthermore, R327 was shown to be superior to the positive control clarithromycin (CLA), a current treatment.1
Infections due to M. abscessus are a major cause of mortality and morbidity in cystic fibrosis (CF) patients.2 Current treatment guidelines recommend a prolonged and intense combination therapy consisting of several antibiotic agents with significant adverse effects.3
Ventilator-associated pneumonia (VAP) is a major concern in healthcare settings, occurring in 9-27% of mechanically ventilated patients.4 Given the high incidence and severity of VAP, R327’s results suggest it could fill a critical gap in the treatment of VAP or similar infections. Hospital-acquired pneumonia (HAP), one of the most common nosocomial infections, is associated with significant clinical and economic burdens, such as long-term hospitalization, high medical costs, and increased morbidity and mortality.5
About
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.
The
Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.
Corporate Contact
+61 (02) 9256 2571
James.graham@recce.com.au
Media & Investor Relations (AU)
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au
Media (
mfitzhugh@lifescicomms.com
Investor Relations (
gvanrenterghem@lifesciadvisors.com
1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192163/
2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431180/
3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431180/
4 https://ccforum.biomedcentral.com/articles/10.1186/cc13775#:~:text=VAP%20is%20estimated%20to%20occur,4%5D%2C%20%5B5%5D
5 https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-021-01816-9
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/5a2526c2-9405-4549-950f-f7436c907a7c
https://www.globenewswire.com/NewsRoom/AttachmentNg/8617b989-ccd3-4ddf-bc1a-5f9d36ad5108
https://www.globenewswire.com/NewsRoom/AttachmentNg/b765c93c-9fb9-47ec-ad7a-0c0f93c22628
Figure 1
M. abscessus lung colonization
Figure 2
Intracellular M. abscessus (1 dpi)
Figure 3
Intracellular M. abscessus (3 dpi)
2024 GlobeNewswire, Inc., source